Product Information
NICOTINE 4 MG MINI LOZENGE is a generic product labeled by Rugby Laboratories, priced at $0.3885 per EA under NDC 00536124181. Its NADAC has been published 350 times since Jan 22, 2020.
FDA first approved this application on Feb 7, 2019.
Strength
4 mg/1
Manufacturer
Rugby LaboratoriesNDC
00536124181
Classification
Generic
Dosage Form
LOZENGE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NICOTINEApproval Type
Generic (ANDA)
FDA Application
ANDA207868FDA Approved
2/7/2019
On Market Since
7/31/2019
Pharmacological Classes
Price Statistics
The NADAC for NICOTINE 4 MG MINI LOZENGE has been published 350 times since Jan 22, 2020, and over the history we have for it it has declined 2.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3885 per EA |
|---|---|
| All-time high | $0.4215 (Jun 10, 2020) |
| All-time low | $0.3337 (May 22, 2024) |
| 52-week high | $0.3906 |
| 52-week low | $0.3568 |
| Median price | $0.3724 |
| Average price | $0.3761 |
| Largest weekly change | +16.5% (Jul 20, 2022) |
| Weeks tracked | 350 |
| Tracking since | Jan 22, 2020 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 11% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rugby Laboratories manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Nicotine Polacrilex market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Nicotinic Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NICOTINE 4 MG MINI LOZENGE?
The current National Average Drug Acquisition Cost (NADAC) for NICOTINE 4 MG MINI LOZENGE, manufactured by Rugby Laboratories, is $0.3885 per EA (NDC 00536124181), effective Sep 30, 2026.
How has the price of NICOTINE 4 MG MINI LOZENGE changed over time?
Over the history we have for it, the NADAC for NICOTINE 4 MG MINI LOZENGE has declined 2.9%. It has been tracked across 350 weekly CMS publications since Jan 22, 2020.
What are the highest and lowest recorded NADAC prices for NICOTINE 4 MG MINI LOZENGE?
Since Jan 22, 2020, the NADAC for NICOTINE 4 MG MINI LOZENGE has ranged from a low of $0.3337 (May 22, 2024) to a high of $0.4215 (Jun 10, 2020), with a median of $0.3724 per EA.
Are there cheaper alternatives to NICOTINE 4 MG MINI LOZENGE?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NICOTINE 4 MG LOZENGE, is $0.3443 per EA — about 11% below NICOTINE 4 MG MINI LOZENGE.
Who manufactures NICOTINE 4 MG MINI LOZENGE?
NICOTINE 4 MG MINI LOZENGE (NDC 00536124181) is labeled by Rugby Laboratories, and CMS classifies it as a generic product.